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Abstract
C9ORF72 mutations are found in a significant fraction of patients suffering from amyotrophic 
lateral sclerosis and frontotemporal dementia, yet the function of the C9ORF72 gene product 
remains poorly understood. Here, we show that mice harboring loss-of-function mutations in the 
ortholog of C9ORF72 develop splenomegaly, neutrophilia, thrombocytopenia, increased 
expression of inflammatory cytokines, and severe autoimmunity, ultimately leading to a high 
mortality rate. Transplantation of mutant bone marrow into wildtype recipients was sufficient to 
recapitulate the phenotypes observed in the mutant animals, including autoimmunity and 
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premature mortality. Reciprocally, transplantation of wildtype marrow into mutant mice improved 
their phenotype. We conclude that C9ORF72 serves an important function within the 
hematopoietic system to restrict inflammation and the development of autoimmunity.
Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of 
motor neurons, resulting in paralysis and death (1). Genetic findings suggest ALS can result 
from mutations in genes acting in several cellular processes (2). To date, the most common 
mutation found in ALS patients, as well as in frontotemporal dementia (FTD), is a 
hexanucleotide repeat expansion in the first intron of C9ORF72 (3). This mutation is present 
in 4-8% of patients with sporadic ALS (4). The repeat expansion is also found in 40% of 
familial ALS cases from Europe and the USA and is even more prevalent in 
Scandinavia(3,4). Identification of unaffected elderly carriers suggests the mutation's effects 
are incompletely penetrant (5).
The expanded GGGGCC repeat in C9ORF72 has been proposed to mediate its effects 
through one or a combination of three mechanisms: the creation of long repetitive 
RNAs(3,6), translation of these RNAs into toxic dipeptides(7), or silencing of the mutant 
allele (3,8,9). Histological and gene expression studies indicate that all three effects of the 
repeat expansion manifest themselves in individuals harboring it. However, which effect, or 
effects of the mutation contribute to the degenerative phenotypes seen in patients remains 
unresolved. The normal protein product of C9ORF72 contains a DENN domain (10) and 
may act as a guanine nucleotide exchange factor (11). Previous studies in fish and worms 
suggested that C9ORF72 might function in the nervous system(8,12). We found that while 
the murine ortholog of C9ORF72 (3110043O21Rik hereafter referred to as C9orf72) is 
widely expressed, it was enriched in motor neurons known to degenerate in ALS (13). 
However, a recent study demonstrated that conditional excision of C9orf72 in cells of the 
nervous system had no overt effects raising the question of whether it plays any role in the 
nervous system or overall health (14).
Resolving the function of the endogenous C9ORF72 gene product remains important as it 
could provide insight into whether the reduction in gene product found in patients with the 
repeat expansion contributes to their disease (3,8,9). Furthermore, efforts are proceeding to 
develop therapeutic approaches for knocking down the gain of function products of the 
repeat expansion (9). As knockdown strategies could inadvertently depress transcription of 
the normal gene product, it will be critical to understand the phenotypic ramifications of 
long-term depression of gene expression from this locus.
Here, we report an initial study of mice harboring loss-of-function mutations in C9orf72. We 
found that homozygous mutant animals produced through homologous recombination as 
well as CRISPR/Cas9 targeting developed several classical features of autoimmunity. 
Transplantation studies demonstrated that mutant bone marrow cells were sufficient to cause 
autoimmunity and premature mortality when placed into otherwise wildtype recipients. 
Thus, we conclude that the gene product encoded by C9orf72 likely acts within the 
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hematopoietic system to play an important role in the promotion of immunological 
tolerance.
Results
Characterization of C9orf72 loss of function mutants
We recently identified the mouse ortholog of C9ORF72, and generated heterozygous mice 
harboring a LacZ insertion replacing exons 2-6 of the gene on an inbred C57BL/6 
background(13) (Fig 1A). Because this targeting event eliminated highly conserved 5′ 
exons of C9orf72 we reasoned that it might result in a loss of gene function, allowing the 
importance of this gene to be investigated. After intercrossing heterozygous (+/-) animals, 
we found that mice of the three expected genotypes were recovered at expected Mendelian 
frequencies (Fig 1B). We designated this strain “KOMP” as the gene targeting to create this 
allele was originally performed by the Knock Out Mouse Project (KOMP) Consortium.
We next sought to use animals from the +/- intercrosses to determine whether the targeted 
mutation reduced expression of C9orf72. Using exon-spanning primers we detected a 
significant, dose dependent reduction in the abundance of transcript sequences from exons 6 
through 8 in whole blood of +/- and -/- animals relative to that found in wild type controls 
(Fig 1C; **p<0.01). To assess whether the mutation also resulted in decreased protein levels, 
we employed two anti-C9orf72 antibodies, one raised against C-terminal regions of the 
protein and the other against its N-terminus. In each case, a band with the predicted mass of 
C9orf72 was significantly depleted in mutant animals (Fig 1D-E; *p<0.05**p<0.01).
There are historical examples of the transcriptional units encoding drug resistance used in 
gene targeting leading to off-target phenotypes(15). We therefore removed the selection 
cassette used for gene targeting by outcrossing C9orf72 targeted KOMP mice with outbred 
animals that expressed the Cre-recombinase under control of the Sox2 promoter (16) 
(hereafter referred to as “Neo deleted”) (Fig 1A; Fig S1A). Intercrosses of +/- Neo deleted 
animals resulted in recovery of +/+, +/- and -/- animals at the expected Mendelian 
frequencies (Fig 1F). Importantly, Neo deleted +/- and -/- mice exhibited a significant and 
dose dependent reduction in C9orf72 transcript abundance (Fig 1G; **p<0.01). As proper 
interpretation of mouse models relies upon the fidelity of the genetic modifications 
introduced, we performed whole genome sequencing of representative +/+, +/-, and -/- 
KOMP animals as well as -/- Neo deleted mice. These studies revealed proper gene targeting 
in each strain and the absence of off-target insertions (Fig S1B). We were also able to 
confirm the C57BL/6 inbred nature of KOMP animals and outbred nature of Neo deleted 
animals (Fig S1C-F).
To determine the effects of C9orf72 loss of function, we intercrossed +/- KOMP animals and 
monitored littermates for 400 days (Fig 2A; n=163; +/+ n=50; +/- n=84; -/- n=29). At 70 
days of age, we noted no obvious phenotypes (Fig 2A). However, as the cohort continued to 
age, the risk of death in both -/- and +/- animals grew to a high level of significance (Fig 2A; 
*p<0.05). We also examined Neo deleted mice generated by +/- intercrosses (Fig 2B; n=50, 
+/+ n=15, +/- n=21, -/- n=14). At later ages we similarly observed significantly increased 
mortality in +/- and -/- mice (Fig 2B; *p<0.05). As C9orf72 has been genetically implicated 
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in ALS, we asked whether increased mortality in mutant animals was associated with neural 
degeneration. However, we did not find obvious changes in the number of spinal motor 
neurons (Fig S2). Nor did we observe differences in the gross histology of the mutant motor 
cortex (Fig S3) or other brain regions of mutant animals (Fig S4). We did however observe 
evidence for increased neural inflammation in the cortex of mutant animals as evidenced by 
focal staining with anti-GFAP antibodies (Fig S5).
We next sought to establish the onset of decline in these mutant animals, to quantify the 
duration of their decline and to better understand the causes of their premature death. We 
weighed mice weekly and performed necropsy on animals found dead or that we were 
obliged to euthanize due to pre-established animal welfare criteria. We noted that while 
animals of all genotypes initially exhibited similar weights, as they aged the weight of both 
KOMP and Neo deleted -/- animals plateaued, and became significantly lower than wild type 
controls (Fig 2C-D; *p<0.05). By defining phenotypic onset for each animal as the age at 
which it reached its maximum body weight, we were then able to quantify the number of 
days that a given animal was burdened by decline prior to its death. Heterozygous animals 
were burdened by decline for on average 118±67 days (KOMP; n=13) and 56±38 days (Neo 
deleted; n=10), while -/- animals were burdened by decline for on average 76±51 days 
(KOMP; n=21) and 37±29 days (Neo deleted; n=9)(Fig 2E). During these studies we 
determined that the causes of demise included cachexia, respiratory failure, hepatomegaly, 
dermatitis, internal hemorrhage, lymphocytic stromal cell hyperplasia, severe ataxia and 
prolapse (Fig 2E; Fig S6).
Upon necropsy of end stage animals, we observed enlarged spleens in KOMP -/- (n=10/11) 
and Neo deleted -/- (n=6/6) mice (Fig 3A-B). Splenomegaly can result from any one of 
several underlying pathologies including infection, myeloproliferative disease, chronic 
lymphocytic leukemia, lymphoma and autoimmunity. To investigate whether any of these 
was the cause of splenomegaly in mutant animals we visually inspected day 300 spleens 
from Neo deleted animals (+/+ n=6, +/- n=3, -/- n=7) and then subjected them to histological 
analysis. We observed a clear demarcation between red and white pulp regions in +/+ and 
+/- spleens, while -/- spleens displayed a disruption of red and white pulp boundaries (Fig 
3B). We next asked when splenomegaly first appeared in these animals. We found that while 
day 25 Neo deleted -/- animals exhibited normal spleen size, by day 50 -/- animals had 
developed significantly enlarged spleens relative to their littermates (Fig 3D; **p<0.01). 
This significant increase in spleen weight was maintained in day 100, day 200 and day 300 
-/- animals (Fig 3D; **p<0.01). We reasoned that splenic vein thrombosis and spontaneous 
microbial infection were less likely causes of splenomegaly in -/- animals due to the 
synchronicity and penetrance at which this phenotype developed.
We next considered the possibility that splenomegaly was the result of lymphoma. In 
lymphoma, individual clonal populations of either B or T cells can dominate the splenic 
compartment. However, mutant animals displayed an increase in splenocytes derived from 
several lineages including CD19+ B220+ B cells, CD3+ CD4+ T cells and CD11b+ Ly6G+ 
neutrophils (Fig 3E-F; Fig S7; *p<0.05**p<0.01). Furthermore, analysis of V(D)J 
recombination in spleens of mutant animals (17) revealed polyclonal populations of B and T 
cells, arguing against the type of clonal expansion observed in lymphoma (Fig 3G). We also 
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did not observe histological changes in the cellularity of -/- bone marrow (Fig S8), which 
can be a site of lymphocytic transformation (18).
In addition to the nearly ubiquitous splenomegaly observed in -/- animals, we also noted that 
a subset of end stage KOMP -/- (n=4/21) and Neo deleted -/- (n=3/9) animals developed 
grossly enlarged cervical lymph nodes (Fig S9). Enlarged lymph nodes can result from 
inflammation, lymphoma, autoimmunity or an inability of lymphocytes to escape this 
compartment (19,20). Although we noted modest changes in the relative proportion of B and 
T cells, both of these populations were greatly expanded within enlarged cervical lymph 
nodes of mutant animals (fig. S9), again arguing against clonal transformation as an 
explanation. Instead we observed an increase in T cell activation state, with a significant 
reduction in CD62Lhi CD44lo cells and a significant increase in CD62Lhi CD44hi and 
CD62Llo CD44hi cells when compared to controls (Fig S9; *p<0.05**p<0.01).
Finally, we noted that a small but significant subset of both KOMP and Neo deleted mutant 
animals developed hepatomegaly (Fig 2E; Fig S10). Histological analysis suggested that this 
liver overgrowth was likely the result of immune cell infiltration (Fig S10). Such immune 
infiltrates in liver can be seen in the context of both leukemia and autoimmunity(21). In this 
case, infiltrating hematopoietic cells appeared morphologically diverse, rather than clonal in 
nature, which again seemed less parsimonious with the diagnosis of leukemia and more 
consistent with chronic inflammation (Fig S10).
Changes in peripheral blood were consistent with autoimmunity not leukemia
Assessing the composition of peripheral blood can yield insight into pathways that disrupt 
the hematopoietic system. We therefore performed whole blood cell counts on mutant mice 
greater than 300 days of age (Fig 4A-H). Numbers of white blood cells, platelets and red 
blood cells in KOMP +/+ and Neo deleted +/+ animals were similar to historic ranges in 
inbred mouse strains(22). In contrast, total white blood cell counts were modestly but 
significantly elevated in KOMP -/- and Neo deleted -/- mice (Fig 4A; **p<0.01), which was 
due to a significant increase in the number of circulating neutrophils (Fig 4B; **p<0.01). We 
observed no significant changes in the relative proportion of peripheral lymphocytes (Fig 
5C) or monocytes in mice of differing genotypes (Fig 4D).
We also noted that platelet count was significantly reduced in KOMP -/- as well as Neo 
deleted -/- animals (Fig 4E; **p<0.01) and that there was a modest but significant reduction 
of red blood cells in KOMP -/- and Neo deleted -/- (Fig 4F; **p<0.01) animals that was 
accompanied by a modest but significant reduction in hematocrit (Fig 4G; **p<0.01). Mean 
corpuscular volume was also reduced in KOMP -/- and Neo deleted -/- animals (Fig 4H; 
**p<0.01), consistent with a modest microcytic anemia. Although there can be many causes 
for changes in red cell and platelet counts, similar phenotypes are seen in autoimmune 
hemolytic anemia and thrombocytopenic purpura, in which red blood cells or platelets, 
respectively, are targeted by auto-antibodies leading to their destruction (23).
To understand how changes in the peripheral blood developed, we bled Neo deleted animals 
(n=164) ranging from 50-200 days of age (Fig 4I-K; +/+ n=49, +/- n=65, -/- n=49). We 
noted that platelet count was already reduced by day 50 in -/- mice and was persistently 
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depressed in older animals (Fig 4K; *p<0.05). Although young animals displayed normal 
neutrophil and white cell numbers, at 100 days of age -/- mice began to exhibit a persistent 
and significant increase in neutrophil numbers (Fig 4J; **p<0.01), which was the primary 
contributor to a significant increase in total white cell counts (Fig 4I; *p<0.05). In contrast, 
numbers of lymphocytes in the blood remained unchanged relative to wild type controls. 
Thus, neutrophilia, thrombocytopenia and splenomegaly were highly penetrant phenotypes, 
which all developed between day 50 and day 100 in -/- animals, suggesting an 
interconnected pathological relationship. In contrast, enlarged lymph nodes and immune cell 
infiltrates in the liver were observed later and at lower frequencies in mutant animals 
suggesting that they could be secondary effects of changes to the hematopoietic 
compartment.
Loss of C9orf72 causes early and chronic cytokine induction
If the splenic and blood phenotypes we observed in -/- animals developed in response to a 
chronic inflammatory process, we reasoned their emergence might be associated with an 
increased abundance of inflammatory chemokines and cytokines. To test this idea, we 
measured the levels of 36 chemokines and cytokines in plasma from day 300 KOMP (Fig 
5A; +/+ n=18, +/- n=8, -/- n=11) and Neo deleted animals (Fig 5B; +/+ n=3, +/- n=11, -/- 
n=4). Eighteen of 36 cytokines and chemokines were significantly elevated in both KOMP 
-/- and Neo deleted -/- animals relative to +/+ controls, including IL-22, IL-28, IL-23, IL-6, 
MCP-1, IL-31, IL-5, IL-10, IL-1β, IL-15/IL-15R, IFNγ, IL-3, GM-CSF, IL-17A, IFNα, 
MIP-1B, LIF and GROα (Fig 5A-B; *p<0.05**p<0.01). No cytokines or chemokines were 
significantly changed in KOMP +/- mice relative to controls (Fig 5A) although we did note 
that IL-28 was significantly elevated and IL-2 was significantly reduced in +/- Neo deleted 
animals relative to controls (Fig 5B; *p<0.05). We next analyzed cytokine levels in cohorts 
of mice at earlier times points. We found that already at 50 days of age, IL-31, IL-15/IL-15R 
and GM-CSF were significantly elevated in Neo deleted -/- mice relative to wild type mice 
(Fig S11; *p<0.05). By 100 days of age Neo deleted -/- animals displayed significantly 
increased levels of 19/36 cytokines and chemokines tested, fully recapitulating the pattern 
observed in older animals at both day 200 and day 300 (Fig S11; *p<0.05**p<0.01). Thus 
the development of an inflammatory cytokine profile was an early event in mutant animals 
that either preceded or was coincident with other blood phenotypes and a decline in health.
Mutant animals rapidly develop persistent autoimmunity
We next considered the possibility that the changes in cytokine levels we found were due to 
autoimmunity. Auto-antibodies targeting double-stranded (ds)DNA are a common diagnostic 
marker of autoimmune syndromes including systemic lupus erythematosus (24). We found 
significant accumulation of anti-dsDNA antibody activity between 50 and 100 days of age in 
Neo deleted -/- animals (Fig 5D; **p<0.01), which was sustained in plasma from KOMP -/- 
and Neo deleted -/- animals greater than 300 days of age (Fig 5C; *p<0.05**p<0.01).
While the accumulation of anti-dsDNA antibodies occurs under conditions of autoimmunity, 
it can also be indicative of rapid but transient cell death (25). To distinguish between these 
two possibilities we used established auto-antigen microarrays to test the plasma of day 300 
Neo deleted littermates for the presence and abundance of IgM and IgG antibodies targeting 
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124 auto-antigens from disparate cell types (26) (Fig 5E, F). In -/- plasma, IgM auto-
antibodies targeting 117/124 antigens were significantly elevated relative to controls. 
Similarly, IgG auto-antibodies targeting 113/124 antigens were significantly elevated in -/- 
animals (Table S1; *p<0.05). In +/- plasma, IgM auto-antibodies targeting 1/124 antigens 
(Liver kidney microsomal type 1; LKM1) were significantly elevated and IgG auto-
antibodies targeting 2/124 antigens (Collagen II and Mi-2) were significantly elevated 
relative to controls (Table S1; *p<0.05). Hierarchical clustering revealed that the pattern of 
IgM auto-antibody activity in 5/6 -/- animals was significantly distinct from +/+ controls and 
2/4 +/- animals (Fig 5E). Intriguingly, the other 2/4 +/- animals displayed an intermediate 
pattern of IgM auto-antibody reactivity, clustering with the remaining -/- mice (Fig 5E). 
Clustering based on IgG-recognized auto-antigens placed all mutants in one distinct group, 
with no obvious distinction between +/- and +/+ found in this case (Fig 5F). Thus, we 
conclude that loss of C9orf72 results in the accumulation of a wide array of self-reactive 
antibodies, which is indicative of an autoimmune phenotype.
As T regulatory cells restrict inflammation, we measured the percentage of CD25+ CD4+ 
cells, which are enriched for this T cell subtype, in spleens from 400 day old Neo deleted 
animals and found that CD25+ CD4+ cells were significantly elevated in -/- spleens relative 
to +/+ animals (Fig S12; **p<0.01).
C9orf72 promotes tolerance in the immune system
The Immgen database(27) indicates that C9ORF72 and its murine ortholog are expressed in 
blood cells. We therefore asked whether C9orf72 acts within the hematopoietic 
compartment. To address this, we performed bone marrow transplantation (BMT) between 
animals of distinct genotypes. Because of their inbred nature, we performed reciprocal BMT 
experiments using KOMP mice. To serve as phenotypic negative and positive controls, we 
transplanted -/- bone marrow into -/- recipients (-/-→-/-)(n=6) and +/+ marrow into +/+ 
recipients (WT→WT)(Fig 6A). To test whether a -/- genotype in bone marrow-derived cells 
was sufficient to cause autoimmunity, we transplanted -/- bone marrow into +/+ recipients 
(-/-→WT)(n=12). Reciprocally, we asked whether loss of C9orf72 in the blood was 
necessary for the development of autoimmunity by attempting to ameliorate the phenotype 
of -/- animals with transplantation of +/+ marrow (WT→-/-)(n=7). B6.SJL-PtprcaPepcb/
BoyJ mice were used as wildtype bone marrow donors and recipients to facilitate tracking of 
reconstitution efficiency (Fig 6A). No animals perished immediately following BMT. By 17 
weeks, 29/30 transplanted animals exhibited >90% reconstitution of CD45+ cells including 
CD11b+ Ly6G- monocytes, CD11b+ Ly6G+ neutrophils, and B220+ B cells (Fig 6B-C; Fig 
S13), indicating engraftment of donor hematopoietic cells was efficient and sustained. 
However, we did note that CD3+ T cell reconstitution was incomplete, ranging from 40 to 
80% donor-derived cells (Fig 6B-C; Fig S13), which can be observed due to the relative 
radio-resistance and long-lived nature of this cell type(28).
All WT→WT animals survived beyond 460 days of age (Fig 6D) and progressively gained 
weight (Fig 6E). In line with our previous findings (Fig 2), we noted that mice lacking 
C9orf72 (-/-→-/-) failed to gain weight as fast as their wild type (WT→WT) counterparts, a 
difference that became significant by 174 days of age (Fig 7E; *p<0.05). Moreover, all -/-
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→-/- animals (n=6/6) died by 350 days, with a median survival of 293 days (Fig 6D; 
*p<0.05), and the causes of death or obligatory euthanasia in -/-→-/- animals were 
consistent with those observed previously (Fig 2E; Fig S13; Video 1). At end stage, -/-→-/- 
mice had developed splenomegaly (Fig 6F; **p<0.01), neutrophilia (Fig 6G; **p<0.01), 
thrombocytopenia (Fig 6H; **p<0.01) and anemia (Fig 6I; **p<0.01). Anti-dsDNA 
antibody activity was significantly elevated in -/-→-/- at an age that preceded mortality (day 
230) (Fig 6J; **p<0.01) as well as at end stage (Fig 6K; **p<0.01). Thus, lethal irradiation 
and bone marrow transplantation did not affect the development of autoimmunity in -/- 
animals.
We asked which of the phenotypes found in -/- animals could be observed in +/+ animals 
receiving -/- bone marrow. We found -/-→WT animals were significantly smaller than 
WT→WT animals at 206 days of age, after which their body weight plateaued (Fig 6E; 
*p<0.05). Strikingly, 9/12 -/-→WT mice died by 460 days of age with a median survival of 
443 days (Fig 6D; *p<0.05 relative to WT→WT ; Video 2). At end stage, all -/-→WT 
(n=9/9) had larger spleens (Fig 6F; **p<0.01), while a subset of -/-→WT mice (3/12) had 
developed enlarged cervical lymph nodes (Fig S13). Relative to WT→WT mice, -/-→WT 
animals had similar numbers of neutrophils (Fig 6G), but displayed a significantly lower 
platelet count (Fig 6H; **p<0.01), and had significantly reduced hematocrit (Fig 6I; 
**p<0.01). IL-22, IL-31 and MIP-1B were significantly elevated in -/-→WT animals 
relative to WT→WT at end stage (Fig S13; *p<0.05). Anti-dsDNA antibody activity was 
similar in -/-→WT and WT→WT animals at day 230 (Fig 6J), yet by end stage -/-→WT 
displayed significantly elevated anti-dsDNA antibody activity (Fig 6K; *p<0.05).
Next we asked whether transplantation of WT bone marrow into -/- animals could improve 
their phenotype. By 230 days of age, WT→-/- mice had gained more weight than their -/-
→-/- counterparts (Fig 6E; *p<0.05). Moreover, WT→-/- animals lived significantly longer 
than -/-→-/- animals, with the longest lived WT→-/- animals surviving to 452 days of age 
and with a median survival of 340 days, representing a 43 day extension of lifespan (Fig 6D; 
*p<0.05 relative to -/-→-/-; Video 3). Splenomegaly was apparent in all WT→-/- animals at 
end stage, but on average their spleens were smaller than -/-→-/- mice (Fig 6F; **p<0.01). 
Relative to -/-→-/- animals, WT→-/- mice had significantly fewer neutrophils (Fig 6G; 
**p<0.01) and significantly elevated platelet counts (Fig 6H; **p<0.01), but hematocrit was 
not significantly improved (Fig 6I). IL-31, IL-6, MIP-1B, IL-10, IL-17A and IL-15/IL-15R 
were significantly reduced in WT→-/- relative to -/-→-/- at end stage (Fig S13; *p<0.05). 
Anti-dsDNA activity was significantly reduced in WT→-/- relative to -/-→-/- animals at day 
230 (Fig 6J; **p<0.01) and at end stage (Fig 6K; *p<0.05).
Generation of C9orf72 mutant mice using CRISPR/Cas9
We noted that some non-coding regions within the deleted locus showed a degree of 
conservation that raised the possibility that their disruption could contribute to the 
phenotypes observed in KOMP and Neo deleted animals. To rule out this possibility, we 
utilized CRISPR/Cas9 technology to induce deletion mutations in exon 4 of C9orf72 (Fig 
7A), an exon present in all transcribed isoforms of both human and murine orthologs. Next 
generation sequencing of PCR amplicons spanning the target site revealed disruption of 
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C9orf72 exon 4 in 23/24 CRISPR/Cas9 targeted mice (Fig 7B, Fig S14; Table S2). In 11/24 
CRISPR/Cas9 targeted animals we identified only premature stop codon mutations and no 
wild type sequences, suggesting that these mice were compound heterozygous loss of 
function mutants for C9orf72 (Fig 7B, Fig S14; Table S2).
All CRISPR/Cas9 targeted mice survived to adulthood, yet as they aged their propensity to 
die increased with only 10/24 animals surviving beyond 500 days of age (Fig 7C). 
Splenomegaly was apparent in all mice (n=7/7) necropsied (Fig 7D-E), while protrusions in 
the neck area indicative of enlarged cervical lymph nodes, were apparent in 3/24 animals 
(Fig S14). Analysis of blood from mutant mice at day 310 revealed a significant reduction in 
hematocrit (Fig 7F; **p<0.01) and a significant increase in anti-dsDNA antibody activity 
(Fig 7G; *p<0.05).
As CRISPR/Cas9 targeted animals were mosaic for mutations in C9orf72, we crossed F0 
mice with C57BL/6 to isolate F1 progeny harboring one wildtype allele and one mutated 
allele (Fig S14). We then interbred F1 progeny containing a 38-nucleotide deletion in 
C9orf72 exon 4, predicted to generate a premature stop codon after 183 amino acids, to 
generate animals that were wild-type (+/+), heterozygous (+/del), and homozygous (del/del) 
for this particular mutation (Fig. 7H and fig. S14). We again found that C9orf72 del/del F2 
mutants displayed significantly elevated anti-dsDNA antibody activity by day 150 (Fig. 7I; 
**P < 0.01).
Discussion
Here we report that eliminating function of mouse C9orf72 predisposes animals to fatal 
immune defects and autoimmunity. We observed that these classic features of autoimmunity 
(24,29) developed synchronously, well before the onset of premature mortality. Furthermore, 
heterozygous animals were more susceptible than control mice to the generation of a limited 
repertoire of auto-antibodies and were at increased risk of early mortality. Chronic 
inflammation is a known contributor to most, if not all of the causes of death we observed in 
+/- and -/- animals. Notably, the pattern of inflammatory cytokines chronically upregulated 
in -/- animals included several members of the IL-23/IL-17 immune axis, which plays a 
pathogenic role in rheumatoid arthritis, psoriasis, Crohn's disease and multiple sclerosis 
(30).
Our findings led us to posit that C9orf72 serves an important function in the hematopoietic 
system. This hypothesis was substantiated by transplant studies in which mutant bone 
marrow transferred autoimmune phenotypes to wildtype recipients and wildtype bone 
marrow suppressed immune deregulation and significantly extended lifespan in mutant 
animals. However, while the phenotype of mutant animals that received wildtype marrow 
was improved relative to mutant mice receiving mutant bone marrow, their phenotype was 
still substantially worse than wildtype animals receiving wildtype bone marrow. Failure of 
wildtype bone marrow to completely rescue mutant mice leaves open the possibility that 
C9orf72 also functions in a radiation-resistant cell population, such as microglia, which are 
peripheral antigen presenting cells the dysfunction of which could lead to improper priming 
of adaptive immune responses., C9orf72 might also function in the thymic epithelium, 
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which is critical for the establishment of peripheral tolerance. Alternatively, T cells 
themselves are well known modulators of immunity and the incomplete replacement of this 
compartment after transplantation provides another potential explanation for the incomplete 
rescue observed. Our findings, and those that indicate T cell function becomes compromised 
in mice harboring mutations in additional ALS-implicated genes (19,31), suggest that 
investigating whether C9orf72 functions in this cell type is warranted. Although we 
observed an increase in the abundance of CD25+CD4+ cells, which are enriched for T 
regulatory cells, in the spleens of mutant animals, whether mutant T regulatory cells harbor 
functional deficits that contribute to the phenotypes we observed remains to be determined. 
Elevation of T regulatory cells could represent a compensatory reaction to reduced 
functionality of this cellular subset or a homeostatic response to persistent inflammation.
We note that our study does have certain limitations and leaves several questions unresolved. 
While our studies demonstrate that bone marrow cells play a role in phenotypes we observed 
and suggests that C9orf72 functions in hematopoietic derivatives of the bone marrow, we 
cannot rule out the possibility that C9orf72 acts through marrow resident mesenchymal 
cells. Additionally, we did not perform an exhaustive census of transplanted animals to 
monitor the extent of engraftment into solid tissues including the brain. Therefore, we 
cannot address whether incomplete imposition or rescue of mutant phenotypes after 
transplant might be due to variable infiltration of cells into a given solid organ(32), rather 
than due to the function of C9orf72 in non-hematopoietic cell types. In the future, it will be 
important to resolve the identity of the specific cell types in which C9orf72 functions to 
preserve a normal immune response. We previously showed that C9orf72 was highly 
expressed in neuronal cell types that are most sensitive to cell death in ALS and FTD, but is 
more modestly expressed in microglia. Despite the high level of C9orf72 expression in the 
neuronal lineage, the data we report here suggests this gene acts through bone-marrow 
derived cells in which it is expressed. It remains to be determined whether C9orf72 serves 
some non-essential function in neurons that express it.
Recently, haploinsufficiency for TBK1, a kinase functioning in interferon signaling and 
selective autophagy(33), has been shown to cause ALS and FTD (Reviewed in 34). Whereas 
Tbk1 -/- mice display an embryonic lethal phenotype, deletion of this gene on an outbred 
background leads to monocytosis, splenomegaly and infiltration of immune cells into the 
skin, lung, liver and kidneys (35). Interestingly, Cre-mediated ablation of Tbk1 in T cells 
resulted in their activation and over accumulation in the spleen and lymph nodes(19). These 
phenotypic commonalities observed upon loss of Tbk1 and C9orf72 are striking. Whether 
these gene products act in a common pathway requires further investigation, however it is 
notable that at least one report has suggested that C9ORF72 may also function in autophagy 
(11).
Whether malfunctions in the immune system directly contribute to degenerative phenotypes 
in ALS patients remains unresolved(36,37). Studies have identified infiltrating T cells and 
hyper-activation of resident immune cells in the post-mortem spinal cords of ALS 
patients(38,39). Patients with a rapid course of disease were also found to have fewer 
circulating T regulatory cells than did individuals with slower disease progression(40), while 
levels of the pro-inflammatory cytokines IL-17 and IL-23 were found to be elevated in 
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plasma and cerebral spinal fluid from at least one ALS cohort(41). Recently, a large 
epidemiologic study found substantially higher rates of autoimmune history in patients 
eventually developing ALS(42). However, studies of auto-antibodies in ALS patients have 
been mixed, with some finding evidence of their presence, while others have not(36,37). The 
ever-improving understanding of the genetic contributors to ALS suggests that revisiting 
immune phenotypes in patients that have been stratified by C9ORF72, TBK1 and other 
genotypes, could now be warranted.
While our manuscript was under review, additional phenotypic studies of C9orf72-deficient 
mice were reported (43,44). These reports both provided direct confirmation of our finding 
that C9orf72 mutant animals develop splenomegaly and lymph adenopathy. Furthermore, 
Atanasio and colleagues found, as we report here, that mutant animals exhibited elevated 
levels of plasma cytokines and autoantibodies (43). However, there were a number of 
differences between our findings and these recent studies that warrant future resolution. 
Most notably, while both we as well as O'Rourke and colleagues generated C9orf72 mutant 
animals using the same targeting vector generated by the Knock Out Mouse Project 
Consortium, heterozygous and homozygous mutants in our colony displayed an increased 
risk of mortality while mutants in their colony did not. This discrepancy suggests that either 
environmental factors or differences in genetic background may influence the longevity of 
mice lacking C9orf72, as is the case with other models of autoimmunity(29). Additionally, 
both Atanasio and O'Rourke found an increase in macrophage number in mutant animals 
and suggested that inflammatory phenotypes found in these mice may be due to dysfunction 
in this or other phagocytic cell-types. Our conclusion that C9orf72 functions in a bone-
marrow derived cells is consistent with this idea. However, we also observed a much broader 
proliferative disorder impacting both myeloid and lymphoid lineages, leaving open the 
question of whether this gene may act in additional hematopoietic cell-types. In the future, 
conditional ablation of C9orf72 in specific blood lineages should address where precisely 
this gene functions to suppress pathological levels of inflammation.
Overall, our findings have implications for planned therapeutic intervention in ALS patients 
harboring the C9ORF72 repeat expansion. Regardless of whether loss of function in 
C9ORF72 plays a central role in the development of ALS, our experiments do strongly 
suggest that therapeutic efforts to reduce expression of the repeat expansion, such as with 
anti-sense oligonucleotides (9), should be designed and carried out with caution. If not, 
chronic depression of the limited quantity of normal gene product that still remains in these 
ALS patients could occur, potentially resulting in autoimmunity.
Materials and Methods
Study design
The goal of this study was to characterize the consequences of C9orf72 loss of function 
mutations in mice. The experimental design involved long-term survival studies paired with 
age-matched and genotype-matched histologic, cellular and biofluidic analysis. Pre-defined 
endpoint criteria included greater than 15% loss of body weight, signs of distressed 
breathing, enlarged abdomen, severe dermatitis, lymph nodes greater than 15 mm that 
inhibited mobility, inability of the mouse to right itself, or severe prolapse. Exploratory 
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experiments were performed in excess of five mice per genotype. Sample sizes for BMT 
studies were calculated using G-power analysis based on previously defined effect sizes. 
Donor and recipient mice were randomized into treatment groups and all outliers were 
included in data analysis. All experimental protocols and procedures were approved by the 
Animal Committee of Harvard University.
RNA extraction and quantitative PCR
Total RNA was isolated using Trizol(GIBCO). First-strand cDNA was synthesized using 
iScript(Biorad). C9orf72 transcripts abundance we analyzed using SYBR Green on CFX96 
Real-time System(ABI). C9orf72 exon 6-8 primers: 5′-
GCAGTGCAGAGAAAGTAAATAAGATAG-3′ and 5′-
ACTGCCTGTTGCATCCTTTAG-3′.
Fixation, sectioning and tissue staining
Mice were anesthetized with Avertin, perfused with PBS then 4% PFA. Tissues were 
harvested and post-fixed in 4% PFA overnight at 4°C. Tissue was dehydrated, embedded in 
paraffin, sectioned at 6um and stained for hematoxylin and eosin. Sections examined in a 
blinded manner and imaged using Zeiss AX10.
Western blotting
Total protein was extracted from frozen brain with a reducing sample buffer (RIPA) 
containing complete inhibitor cocktail(Roche). 15ug of protein was separated on 4-20% 
SDS-polyacrylamide gel, transferred to pvdf membrane, blocked with 5% BSA, incubated 
with primary antibodies (anti-C9ORF72-N-terminal(ProteinTech), anti-C9ORF72-C-
terminal(Abgent), anti-α-tubulin(Abcam)) and detected by enhanced 
chemiluminescence(GE Amersham).
Blood and cytokine measures
Peripheral blood was collected via mandible puncture into EDTA-coated tubes. Blood 
counts were assessed using a Hemavet(Abaxis), then centrifuged to pellet cells and plasma 
harvested from supernatant. Luminex-based multiplexed fluorescence assay was used to 
assess 36 cytokines and chemokines.
Auto-antibody profiling
Plasma was diluted 1:200 and assessed using mouse α-dsDNA total-Ig kit(Alpha Diagnostic 
International). Antibodies against 124 autoantigens were measured on autoantigen 
arrays(26).
Spleen and lymph node FACS
Spleens were mashed between two glass slides and passed repeatedly through a 25 5/8G 
needle to dissociate single cells. Following RBC lysis, cells were quantified using a 
Countess(Invitrogen). Lymph nodes were processed as above without RBC lysis. Cells 
stained using these antibodies(Biolegend): B220(RA3-6B2), CD19(6D5), Kappa(RMK-45), 
Lambda(RML-42), CD11c(N418), CD8α(53-6.7), CD3ε(145-2C11), CD4(GK1.5), 
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CD62L(MEL-14), CD44(IM7), CD25(PC61), Pan-NK(DX5), CD11b(M1/70), Ly6G(1A8), 
CD115(AFS98), F4/80(BM8), and DAPI(Sigma).
Bone marrow transplantation
Female B6.SJL-PtprcaPepcb/BoyJ(Jackson Labs) mice were used as age matched WT bone 
marrow donors and recipients. Female KOMP C9orf72 -/- mice were used as age matched 
bone marrow donors and recipients. At D110, marrow from femur and tibias were harvested 
from two WT and two -/- donors, flushed, single cell dissociated, counted, pooled and 
diluted to 5E6 cells/100uL. Recipient animals received two rounds of 550rad separated by 3 
hours. 5E6 bone marrow cells were injected into the tail vein. Recipients were maintained on 
pH 3.0 water for two weeks. Reconstitution efficiency in RBC-lysed peripheral blood at 17 
weeks post-transplant was measured using these antibodies(Biolegend): CD45.2(104), 
CD3ε(145-2C11), B220(RA3-6B2), Ly6G(1A8), CD11b(M1/70), CD45.1(A20).
CRISPR/Cas9 sequencing
Tail DNA was PCR amplified with primers containing flanking adaptors followed by PCR 
barcoding with 24 unique barcodes. Samples were pooled, cleaned (Promega Wizard DNA-
cleanup kit), sequenced via MiSeq and analyzed(45).
Statistics
All statistical calculations were performed using Graphpad Prism. Tests between two groups 
used two-tailed Student t-test. Tests between multiple groups used One-way ANOVA with 
Tukey's multiple comparisons. Tests between multiple groups over time used Two-way 
ANOVA with Dunnett's multiple comparisons. Survival curves were evaluated by 
Generalized Wilcoxon.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Editor's Summary
C9orf72 acts in hematopoietic cells to suppress autoimmunity
Mutations in C9ORF72 are a common contributor to amyotrophic lateral sclerosis and 
frontotemporal dementia, yet the function of this gene is still poorly defined. In new 
work, Burberry et al. demonstrate that mutations disrupting the normal function of 
C9orf72 cause mice to develop features of autoimmunity. They further found that 
transplantation of normal bone marrow into mutant animals ameliorated their condition, 
whereas transplantation of mutant bone marrow into normal animals was sufficient to 
cause autoimmunity. The authors conclude that C9orf72 acts through hematopoietic cells 
to maintain normal immune function and suggest that investigations into whether 
disruptions in immunity contribute to disease in patients are warranted.
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Fig. 1. A loss of function mutation in the C9orf72 ortholog
(A) The schematic illustrates replacement of exons 2-6 to generate the KOMP allele and 
crosses with Sox2-cre mice to generate the Neo-deleted allele. (B) Frequency of genotypes 
born from KOMP +/- crosses. (C) C9orf72 expression in KOMP whole blood by 
quantitative RT-PCR. **p<0.01 Tukey's multiple comparisons. ns not significant. (D) 
Western blotting of cortical tissue from the 3 KOMP genotypes using anti-C9ORF72 
antibodies. (E) Quantification of Western blot bands. *p<0.05 **p<0.01 Tukey's multiple 
comparisons. (F) Frequency of genotypes born from Neo deleted +/- crosses. (G) C9orf72 
expression in Neo deleted whole blood by quantitative RT-PCR. **p<0.01 Tukey's multiple 
comparisons.
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Fig. 2. C9orf72 mutations lead to premature death of mice
Mice harboring loss of function mutations in C9orf72, generated by homologous 
recombination using a targeting vector in embryonic stem cells on C57BL/6 background 
(KOMP) and those outcrossed with Sox2-cre expressing mice to remove the neomycin 
cassette (Neo deleted), were aged for survival studies. Kaplan Meier survival curves for (A) 
KOMP and (B) Neo deleted mice. *p<0.05, **p<0.01 Generalized Wilcoxon test. Body 
weight of female (C) KOMP mice and (D) Neo deleted animals over time. *p<0.05 
Dunnett's multiple comparisons. (E) Cause of death or obligatory euthanasia in KOMP and 
Neo deleted mice. Days of decline indicates time between maximum body weight (onset) 
and death or obligatory euthanasia.
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Fig. 3. Identity of cells within the enlarged mutant spleens of Neo deleted mice
(A) Spleens from day 300 Neo deleted animals. Scale bar, 1 cm. (B) Hematoxylin & eosin 
staining of spleens from Neo deleted mice at day 300. Scale bar (i) 500 micron and (ii) 50 
micron. (C, D) Quantification of spleen weight in (C) end stage KOMP and Neo deleted 
animals and (D) aged Neo deleted animals. C,E,F *p<0.05, **p<0.01 Tukey's multiple 
comparisons. (D) *p<0.05, **p<0.01 Student t-test. ns not significant. (E) Splenocyte counts 
from day 200 Neo deleted mice. (F) Quantification of splenocyte subsets in day 200 Neo 
deleted mice. (G) PCR analysis of T cell and B cell clonality in the spleens of day 400 Neo 
deleted mice. LN2 and LN3 represent ESCs generated by nuclear transfer from lymph node-
derived T cells that harbor monoclonal TCRβ rearrangements.
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Fig. 4. Mice with C9orf72 mutations develop hematological phenotypes
(A-H) Peripheral blood counts assessed for day 300+ KOMP and Neo deleted animals. 
*p<0.05, **p<0.01 Tukey's multiple comparisons. ns not significant. (A) White blood cells 
(B) Neutrophils (C) Lymphocytes (D) Monocytes (E) Platelets (F) Red blood cells (G) 
Hematocrit (H) Mean corpuscular volume. (I-K) Peripheral blood counts assessed for aged 
Neo deleted animals. (I) White blood cells (J) Neutrophils (K) Platelets.
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Fig. 5. Mice with C9orf72 mutations show increased cytokines, chemokines and auto-antibodies
(A, B) Analysis of 36 plasma cytokines and chemokines in day 300+ (A) KOMP and (B) 
Neo deleted animals. *p<0.05, **p<0.01 Tukey's multiple comparisons. ns not significant. 
(C, D) Anti-double stranded (ds)DNA antibody reactivity in plasma of (C) day 300+ KOMP 
and Neo deleted animals and (D) aged Neo deleted animals. (E, F) Plasma from day 300+ 
Neo deleted mice assessed for (E) IgM and (F) IgG reactivity against 124 self-antigens (26). 
Unsupervised hierarchical clustering grouped individual animals (x-axis) and self-antigens 
(y-axis).
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Fig. 6. C9orf72 acts in bone marrow derived cells to prevent autoimmunity
(A) Wild type or C9orf72 deficient animals were lethally irradiated at day 110 and 
reconstituted with wild type or mutant bone marrow. Recipient mice were regularly 
weighed, monitored for survival and bled for whole blood counts and plasma analyses and 
necropsied at end stage. (B, C) Quantification of flow cytometry-based assessment of 17 
week post-transplant peripheral blood reconstitution. (B,C, F-K) Each dot represents one 
mouse. (D) Survival curves for transplanted mice. *p<0.05 Generalized Wilcoxon test. (E) 
Average body weight ± SEM. *p<0.05 Dunnett's multiple comparisons. (F) End-stage 
spleen weight. (F-K) *p<0.05, **p<0.01 Tukey's multiple comparisons. ns not significant. 
(G) End-stage peripheral blood neutrophil counts. (H) End-stage peripheral blood platelet 
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counts. (I) End-stage hematocrit. (J-K) Plasma anti-dsDNA antibody activity in animals at 
(J) day 230 and (K) end-stage.
Burberry et al. Page 24
Sci Transl Med. Author manuscript; available in PMC 2017 January 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 7. CRISPR/Cas9 induced mutations in C9orf72 lead to autoimmunity
(A) Schematic showing the CRISPR/Cas9 targeting strategy to cause DNA double strand 
breaks in exon 4 of C9orf72, resulting in several distinct mutations. (B) DNA sequences 
from CRISPR/Cas9-targeted mice indicated that 23/24 animals harbored a stop codon in 
exon 4 of the C9orf72 gene. (C) Survival of CRISPR/Cas9 targeted mice. (D) Spleens from 
a CRISPR/Cas9-targeted mouse at end-stage and age-matched C57BL/6 control. (E) Spleen 
weights for CRISPR/Cas9 mutant and KOMP mice. (E-G) Each dot represents one mouse. 
*p<0.05 **p<0.05 Dunn's multiple comparisons. (F) Hematocrit for day 300+ CRISPR/
Cas9-targeted animals. (G) Plasma anti-dsDNA antibody activity in day 300+ CRISPR/Cas9 
targeted animals. (H) Mice harboring a 38-nucleotide deletion in exon 4 of C9orf72 were 
bred to heterozygosity (+/del) and homozygosity (del/del), as visualized by PCR of tail DNA 
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using primers flanking the deletion site. (I) Plasma anti-dsDNA antibody reactivity in day 
150 +/+, +/del and del/del animals. **p<0.01 Tukey's multiple comparisons. ns not 
significant. (J) Proposed model for how C9orf72 may act in bone marrow-derived cells to 
limit fatal immune deregulation.
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